Althobaiti, F.M.; Alsanosi, S.M.; Falemban, A.H.; Alzahrani, A.R.; Fataha, S.A.; Salih, S.O.; Alrumaih, A.M.; Alotaibi, K.N.; Althobaiti, H.M.; Al-Ghamdi, S.S.;
et al. Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study. J. Clin. Med. 2022, 11, 4769.
https://doi.org/10.3390/jcm11164769
AMA Style
Althobaiti FM, Alsanosi SM, Falemban AH, Alzahrani AR, Fataha SA, Salih SO, Alrumaih AM, Alotaibi KN, Althobaiti HM, Al-Ghamdi SS,
et al. Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study. Journal of Clinical Medicine. 2022; 11(16):4769.
https://doi.org/10.3390/jcm11164769
Chicago/Turabian Style
Althobaiti, Fahad M., Safaa M. Alsanosi, Alaa H. Falemban, Abdullah R. Alzahrani, Salma A. Fataha, Sara O. Salih, Ali M. Alrumaih, Khalid N. Alotaibi, Hazim M. Althobaiti, Saeed S. Al-Ghamdi,
and et al. 2022. "Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study" Journal of Clinical Medicine 11, no. 16: 4769.
https://doi.org/10.3390/jcm11164769
APA Style
Althobaiti, F. M., Alsanosi, S. M., Falemban, A. H., Alzahrani, A. R., Fataha, S. A., Salih, S. O., Alrumaih, A. M., Alotaibi, K. N., Althobaiti, H. M., Al-Ghamdi, S. S., & Ayoub, N.
(2022). Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study. Journal of Clinical Medicine, 11(16), 4769.
https://doi.org/10.3390/jcm11164769